GW Phar­ma shares dent­ed af­ter cannabi­noid drug fails a PhI­Ia study on fo­cal seizures

Af­ter round­ing up a con­sid­er­able port­fo­lio of promis­ing late-stage da­ta for its cannabis-based an­ti-con­vul­sive drug Epid­i­olex, the UK’s GW Phar­ma­ceu­ti­cals re­port­ed af­ter the mar­ket closed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER